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Increasing Heart Failure Incidence in
Elderly Patients With First Myocardial Infarction
Justin A. Ezekowitz, MBBCH, MSC,* Padma Kaul, PHD,* Jeffery A. Bakal, PHD,†
Paul W. Armstrong, MD,*† Robert C. Welsh, MD,* Finlay A. McAlister, MD, MSC‡
Edmonton, Alberta, Canada
Objectives The purpose of this study was to examine the long-term incidence of heart failure (HF) in elderly patients with
myocardial infarction (MI).
Background In-hospital HF is common after MI and is associated with poor short-term prognosis. Limited data exist concern-
ing the long-term incidence or prognosis of HF after MI, particularly in the era of coronary revascularization.
Methods A population-based cohort of 7,733 patients 65 years of age hospitalized for a first MI (International Classifica-
tion of Diseases-9th Revision-Clinical Modification code 410.x) and without a prior history of HF was established
between 1994 and 2000 in Alberta, Canada, and followed up for 5 years.
Results During the index MI hospitalization, 2,831 (37%) MI patients were diagnosed with new HF and 1,024 (13%)
died. Among hospital survivors who did not have HF during their index hospitalization (n  4,291), an additional
3,040 patients (71%) developed HF by 5 years, 64% of which occurred in the first year. In total, 5,871 (76%)
elderly patients who survived their first MI developed HF over 5 years. Among those who survived the index hos-
pitalization, the 5-year mortality rate was 39.1% for those with HF during the index MI hospitalization compared
with 26.7% among those without HF (p  0.0001) during the index MI hospitalization. Over the study period, the
5-year mortality rate after MI decreased by 28%, whereas the 5-year rate of HF increased by 25%.
Conclusions In this large cohort of elderly patients without a history of HF, HF developed in three-quarters in the 5 years after
their first MI; this proportion increased over time as peri-MI mortality rates declined. New-onset HF significantly
increases the mortality risk among these patients. (J Am Coll Cardiol 2009;53:13–20) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.067e
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Mhe incidence and prevalence of heart failure (HF) in adults
s increasing. Given the high prevalence of cardiovascular
isk factors, an increasing global burden of HF, in both
eveloped and developing countries, seems assured (1,2). In
he U.S. alone, HF accounted for approximately 727,000
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ccepted August 18, 2008.mergency department visits, 1 million hospital admissions,
nd an estimated overall annual cost of $29 billion for 2006
3,4). Whereas the poor prognosis of HF patients is
stablished, less is known concerning the events that pre-
ede the development of HF.
See page 21
Although ischemic heart disease is well recognized as a
rincipal cause of HF, the incidence, prevalence, and time
ourse for the development of HF after myocardial infarc-
ion (MI) is unclear. In patients presenting with an MI and
oncurrent in-hospital HF, early (i.e., within 6 months)
ost-discharge mortality is nearly 4-fold higher than in
hose without HF (5). An Australian study showed that
atients younger than 65 years of age presenting with their
rst MI in whom HF developed early (28 days from index
I) had a greater likelihood of HF admission or mortalityver the next decade (6). Surprisingly, the incidence of
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Post-MI HF December 30, 2008/January 6, 2009:13–20late-onset HF was strikingly low;
only 9% were hospitalized for
HF in the next decade, leading to
speculation of under-reporting of
HF. An earlier study of all Al-
bertans who survived their first
MI between 1994 and 1999
found that HF developed in 29%
over 32 months; however, that
study included patients of all ages
and did not have access to med-
cation data (7). Few studies have examined the effect of the
entinel event of developing HF in long-term follow-up
ost-MI. Data from 200 MI patients in the original
ramingham cohort showed a 14% incidence of HF
ost-MI over the next 5 years: nearly one-half of those
atients subsequently died (8). Few patients age 65 years or
lder have been enrolled in clinical trials or registries,
espite their increased risk for complications or mortality
fter MI (9). Given the modest sample size and advances in
edical care, a more contemporary cohort not limited to
hose in a select registry or clinical trial is required to best
ddress the question of whether advances in MI care have
ncreased or reduced the subsequent incidence of HF.
We describe the incidence and temporal trends of HF
uring and after MI, and the subsequent risk for death after
eveloping HF are described using a 6-year community-
ased cohort of all patients age 65 years or older with an
cute MI hospitalized in a large geographic region with
niversal health care coverage.
ethods
atabases. The Alberta Elderly MI cohort was created by
dentifying the first MI hospitalization and following up the
atient’s physician visits, emergency department visits, and
ospitalizations for 5 years. The database was created by
inking 5 separate databases maintained by Alberta Health
nd Wellness in Alberta, Canada: 1) the Discharge Abstract
atabase, which records information (including dates, di-
gnoses, and procedures) on all admissions to any of the
cute care facilities in Alberta; 2) the Ambulatory Care
atabase, which records all visits to hospital-based physi-
ians’ offices and all emergency departments; 3) the Physi-
ian Claims Database, which records all claims for service
by diagnostic code) made by physicians for the outpatient
are of patients in physicians’ offices; 4) the Alberta Health
are Insurance Registry, which tracks the vital status of all
lbertans; and 5) the Blue Cross Medication Database,
hich includes hospital discharge and outpatient prescrip-
ion medication data on all patients 65 years of age or older.
ata on aspirin use (because of its availability over the
ounter in Alberta) or therapy with thrombolytic agents,
eparin, or other acute in-hospital agents are not available.
ach individual has a unique health care number by which
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
HF  heart failure
MI  myocardial infarction
STEMI  ST-segment
elevation myocardial
infarctionatient information can be followed up through each of the Catabases. Deaths were identified using the Alberta Health
are Insurance Registry and the Discharge Abstract Data-
ase, which provide the details on date of death and location
in or out of hospital).
The cohort consists of patients 65 years of age who had
een hospitalized for a primary diagnosis of acute MI
International Classification of Diseases-9th Edition-
linical Modification [ICD-9-CM] 410.x) between April
, 1994, and March 31, 2000. Patients with a prior
dmission for MI or HF in the last year were excluded. The
atients were followed up until death or 5 years after the
nitial MI hospitalization, with the follow-up ending on
pril 1, 2005.
efinitions of outcomes and covariates. Concurrent HF
as defined as HF developing as a complication of the index
I; subsequent HF was defined as a hospitalization or
hysician claim for HF (ICD-9-CM 428.x; previously
alidated with specificity of 95% to 96% vs. chart audit gold
tandard [10,11]) occurring after the index MI. Time to HF
as defined as the time of discharge if the HF occurred as
complication of the index MI or the time of subsequent
dmission for subsequent hospitalizations.
Identification of comorbidity was performed using the
CD-9-CM codes at the incident hospitalization or if there
as an additional hospitalization or physician claim in the next
0 days. The 30-day window was selected to enrich the data
ver that acquired during the index hospitalization while
itigating survivor bias. The accuracy of our data acquisi-
ion, the use and accuracy of discharge coding to identify
ases and comorbidities, and hospital and specialist infor-
ation have been described elsewhere (12–14). Location of
eath was divided into hospital or out-of-hospital as done
reviously (15); cause of death was unavailable.
To describe other non-HF hospitalizations, intercurrent
ospitalizations (with clinical relevance and an incidence of
1%) during the first year are provided for descriptive
urposes for patients discharged alive after the index MI.
he primary diagnosis for hospitalization is provided in 4
ategories: alive and did not develop HF, alive and devel-
ped HF, died after developing HF, and died without
eveloping HF.
Evidence-based medications for the index MI were de-
ned as angiotensin-converting enzyme (ACE) inhibitors,
eta-blockers, and 3-hydroxy-3-methylglutaryl-coenzyme
reductase inhibitors (statins). Per prior studies using these
dministrative databases, a window of 30 days after the
ospital discharge was used to identify prescriptions that
ould be linked to the hospital visit after discharge. Because
ur primary interest was development of subsequent HF,
nformation regarding medications is provided on those
atients discharged alive after their index MI.
tatistical analyses. Continuous baseline variables were
ompared using standard estimation methods, using mean
SD) and t tests or medians with interquartile ranges and
ilcoxon tests for continuous data where appropriate.
ount data were summarized using percentages, relative
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December 30, 2008/January 6, 2009:13–20 Post-MI HFisks, and chi-square tests. Temporal trends were examined
sing the Cochran-Armitage test. A further analysis was
erformed using age in 3 categories (65 to 69 years of age,
0 to 75 years of age, and older than 75 years of age)
quivalent to the 25th and 50th percentile of age in the
tudy cohort. A multistate model was constructed based on
he work of Putter et al. (16). Inclusion of factors for the
ultistate model from the univariate analysis was done if
 0.20. The multistate model was developed by first
dentifying 3 clinically important states: the index MI
ospitalization, subsequent HF, and death. The transitions
o be modeled are from MI to HF development with death
ithout HF as a competing risk, and then a third to allow
he modeling of prognostic indicators of death among those
 n=771
 n=2316
No events
n=1091
Heart Failure
n=5871
Death
Figure 1
Multistate Model of Transitions for Patients
Through 3 Clinically Important States: The Index MI
Hospitalization, Subsequent Heart Failure, and Death
MI  myocardial infarction. Figure illustration by Rob Flewell.
aseline Characteristics of All Patients at Index Myocardial Infarct
Table 1 Baseline Characteristics of All Patients at Index Myoc
Variable
At Index Myocardial Infarctio
No HF Dev
n (%) 4,902 (63.4%) 2,831
Age, yrs, median (IQR) 74.5 (69.7–80.3) 75.5
Female 41.3
Diabetes 16.7
Hypertension 35.3
Cardiac arrhythmia 23.1
Atrial fibrillation 9.6
Peripheral arterial disease 2.7
Cerebrovascular disease 4.9
Acute renal disease 1.9
Chronic renal disease 1.5
COPD 12.9
Cancer 2.3alues are percents unless otherwise stated.
COPD  chronic obstructive pulmonary disease; HF  heart failure; IQR  interquartile range.ho have developed HF. The schematic for this model with
he patient numbers from our study are given in Figure 1.
his model allows the estimation of prognostic factors both
or each transition separately or as a single unit if the factor
as a similar effect regardless of transition. Additionally, by
sing the clock-forward method (16), patients in the HF
roup are left-censored until they enter the state, allowing
atients to enter the HF state (when they develop HF) and
eave if they die or reach the end of the 5-year follow-up. To
urther explore potential bias inherent in the model we
reated, the analysis was then repeated on a subset of
atients (n  4,291) who left the hospital alive after their
ndex MI who had not developed in-hospital HF as a
omplication of their MI. Results are presented as odds
atios (ORs), relative risks (RRs), or hazard ratios (HRs)
ith 95% confidence intervals (CIs) where appropriate; a p
alue of 0.05 was taken as statistically significant. All
nalyses were done using R version 2.6.1 (17) and SAS
ersion 9.1 (SAS Institute Inc., Cary, North Carolina).
esults
total of 11,479 elderly patients were identified with MI
etween April 1, 1994, and March 31, 2000. Patients with
rior HF were excluded from the cohort (n  2,523,
1.9%), as were those with prior MI (n  1,688, 14.7%),
esulting in a final study population of 7,733 patients
median age 75 years, 60.0% male) with a first MI and no
rior HF who were followed up for up to 5 years.
ndex hospitalization. During the index MI hospitaliza-
ion, 2,831 (36.7%) patients were diagnosed with HF.
atients developing HF during the index hospitalization
ere more likely to be older, to be male, and to have
ypertension, diabetes, other vascular disease, chronic ob-
tructive pulmonary disease, and renal disease (Table 1).
edical therapy and invasive revascularization also differed
etween these 2 groups (Table 2). Patients who developed
l Infarction
Relative Risk for Developing HF
During the Index Hospitalization p ValueHF
)
81.1) 0.001
0.86 (0.78–0.95) 0.0022
1.51 (1.35–1.70) 0.0001
1.40 (1.27–1.54) 0.0001
1.91 (1.73–2.11) 0.0001
2.43 (2.13–2.77) 0.0001
2.49 (1.98–3.13) 0.0001
1.55 (1.28–1.88) 0.0001
2.45 (1.87–3.21) 0.0001
4.24 (3.20–5.62) 0.0001
1.37 (1.21–1.56) 0.0001
1.50 (1.14–1.98) 0.004ion
ardia
n
eloped
(36.6%
(70.5–
37.8
23.2
42.3
36.5
20.4
6.5
7.4
4.5
5.9
16.9
3.4
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Post-MI HF December 30, 2008/January 6, 2009:13–20F at the index MI were more likely to have undergone
evascularization; more likely to receive ACE inhibitors,
ngiotensin receptor blockers, warfarin, or diuretics; and less
ikely to have received beta-blockers or nitrates.
From 1994 through 2000, there was a 28.1% relative
eduction in mortality during the index hospitalization
from 18.1% to 13.0%, p  0.01) (Fig. 2). In the same
eriod, the incidence of in-hospital HF among survivors
ncreased 25.1% (from 31.4% to 39.3%, p  0.001). The
ean length of stay decreased over time from 1994 (mean
.5 days [SD 7.6]) to 2000 (mean 7.8 [SD 6.9]), p  0.01.
edication use within 30 days of discharge increased from
994 to 2000, for ACE inhibitors (25.3% to 45.1%),
eta-blocker (44.2% to 65.6%), and statins (1.5% to 23.3%)
all p  0.001).
ong-term follow-up. In addition to the 2,831 patients
36.6%) who were diagnosed with HF during their index
I hospitalization, an additional 3,040 of the 4,291 pa-
ients that survived the index MI without HF (70.8%)
eveloped HF in the subsequent 5 years. Most of these
atients (n  1,612, 53.0%) developed HF in the first year,
ith the remainder distributed uniformly over the remain-
ng 4 years. Thus, three-quarters of the cohort developed
F (n  5,871, 75.9%) during the 5 years after their first
I. Mortality rate among patients who developed HF and
urvived their index MI was 39.1% at 5 years, compared
ith 26.7% among patients who did not develop HF during
heir index MI hospitalization (RR: 1.8, 95% CI: 1.6 to 2.0,
 0.0001). After the index MI, death occurred more
edical Therapy and Invasiveoron ry R v scularization Within0 Days of Index Myocardial Infarction
Table 2
Medical Therapy and Invasive
Coronary Revascularization Within
30 Days of Index Myocardial Infarction
Variable
At Index Myocardial Infarction
p ValueNo HF Developed HF
n (%) 4,902 (63.4%) 2.831 (36.6%)
Any invasive coronary
revascularization
12.4 16.8 0.0001
Stent 6.0 8.7 0.0001
PCI 10.6 13.9 0.0001
CABG 1.9 3.2 0.0006
ACE inhibitor 31.8 39.3 0.0001
ARB 1.4 2.7 0.0003
Beta-blocker 58.7 49.6 0.0001
Calcium-channel
blocker
3.6 3.4 0.796
Statin 12.7 10.5 0.007
Nitrates 64.0 53.4 0.0002
Sublingual 47.5 40.3 0.0001
Pill or patch 27.0 30.1 0.008
Warfarin 8.6 12.4 0.0001
Diuretics 10.8 23.0 0.0001
alues are percents unless otherwise stated. Medication data only for those who survived index
ospitalization.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronary
rtery bypass grafting; HF  heart failure; PCI  percutaneous coronary intervention.requently in-hospital for those patients who developed HFompared with the non-HF group (64.8% vs. 30.2% respec-
ively, p  0.001).
As a further analysis, patients were stratified by age based
n the 25th and 50th percentiles (65 to 69 years of age, 70
o 75 years of age, and 75 years of age). Of patients who
ere 65 to 69 years of age at the time of their first MI,
3.0% developed HF and 5.2% died at their index MI, and
fter discharge 50.2% who did not have in-hospital HF
eveloped HF and 55.7% died within 5 years. Thus, 70.6%
f patients age 65 to 69 years developed HF in the 5 years
fter their first MI. For the patients 70 to 75 years of age,
5.7% developed HF and 9.2% died at their index MI, and
fter discharge 57.9% of those without HF developed HF
nd 61.7% died. Thus, 75.1% of patients age 70 to 75 years
eveloped HF in the 5 years after their first MI. For the
atients older than 75 years of age, 39.0% developed HF
nd 19.6% died at their index MI, and after discharge 65.4%
f those free of HF developed HF and 70.3% died. Thus,
6.8% of patients older than 75 years of age developed HF
n the 5 years after their first MI. All of these comparisons
ere all highly statistically significant across age strata
p  0.0001).
Intercurrent hospitalizations in the first year after being
ischarged alive from the index MI occurred frequently
Table 3). By the end of the first year, a substantial
70
60
50
40
30
20
10
0
1994 1995 1996 1997 1998
In-hospital mortality
In-hospital heart failure
Cumulative heart failure 
in next 5-years*
Cumulative 5-years mortality
Year of Index MI
%
1999
Figure 2 Temporal Trends in Mortality
Rate and the Development of Heart Failure
Black bars indicate in-hospital mortality rate, and red bars indicate in-hospital
heart failure rate. Red line indicates cumulative heart failure in the next 5
years for patients who survived index hospitalization, and black line indicates
the cumulative 5-year mortality. X-axis indicates year of hospitalization for index
myocardial infarction (MI).
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December 30, 2008/January 6, 2009:13–20 Post-MI HFroportion of patients (18.1%) had been rehospitalized for
nother MI. Those who were alive at the end of the first
ear and had developed HF were more likely to have had
epeat MI, an acute ischemic event, or other intercurrent
ospitalization.
redictors of mortality or HF. The multistate model
Table 4) describes variables predictive of the development
f: 1) HF, and 2) mortality (whether or not they developed
F). Similar variables predicted the development of HF
nd mortality. Of note, users of beta-blockers and statins
fter the index MI were less likely to develop HF, and ACE
nhibitors, beta-blockers, and statins were associated with
educed mortality in both those patients who did develop
F post-MI and those who did not develop HF. Further,
lthough invasive coronary revascularization (percutaneous
oronary intervention with or without stent placement or
ntercurrent Hospitalizations in the First Year After Index Myocardi
Table 3 Intercurrent Hospitalizations in the First Year After Ind
Disease
Alive at End of First Yea
No HF Deve
n (%) 5,300 (79.1) 70
Myocardial infarction 16.5
Other acute ischemic heart disease 5.4
Angina 2.8
Atrial fibrillation 1.4
Ventricular arrhythmias 0.3
COPD 0.4
Cerebrovascular disease 1.0
Renal disease 0.2
nly primary hospitalized diagnoses with clinical relevance and an incidence 1% are included.
dition-Clinical Modification (ICD-9-CM) codes were used: myocardial infarction (ICD-9-CM 410), o
27.3), ventricular arrhythmias (ICD-9-CM 427.1/4/5), chronic obstructive pulmonary disease (CO
04, 584, 585).
HF  heart failure.
ultivariable Multistate Modeling for Predictors of Heart Failure or
Table 4 Multivariable Multistate Modeling for Predictors of Hea
All Patients
(n  7,733), %
Develop
(n 
HR (
Age, per yr 1.02 (1
Female 40.0 1.07 (1
Diabetes 19.1 1.21 (1
Cardiac arrhythmia 28.0 1.25 (1
Peripheral vascular disease 4.1 1.36 (1
Cerebrovascular disease 5.8 1.13 (1
Acute renal failure 2.9 1.32 (1
Chronic renal failure 3.1 1.51 (1
COPD 14.3 1.15 (1
Cancer 2.7 1.24 (1
PCI without stent 4.8 1.02 (0
PCI with stent 7.0 1.08 (0
CABG 2.4 1.10 (0
ACE inhibitors 29.9 1.26 (1
Beta-blockers 48.0 0.83 (0
Statins 10.3 0.91 (0
Year (1997 to 2000, reference 1994 to 1996) 51.4 1.11 (1I  confidence interval; COPD  chronic obstructive pulmonary disease; HR  hazard ratio; other abbreypass surgery) was not associated with the risk of develop-
ng HF in the multivariate analyses, patients who had
ndergone invasive coronary revascularization were less
ikely to die, whether or not they developed HF. In the
ubset of patients discharged alive from the hospital who did
ot develop HF as a complication of their MI, the model
id not substantially change with 1 exception: ACE inhib-
tors were no longer associated with reduced mortality in
hose patients developing HF (OR: 1.04, 95% CI: 0.90
o 1.20).
iscussion
n this large cohort of elderly MI patients without a history
f HF, almost three-quarters developed HF within 5 years.
mportantly, this substantial HF incidence tracked a reduc-
arction
yocardial Infarction
Died in First Year
p ValueHF No HF Developed HF
) 488 (7.3) 206 (3.1)
26.6 24.3 0.0001
5.3 8.7 0.0002
1.4 2.9 0.0001
1.0 3.4 0.0012
1.8 1.9 0.0001
1.0 2.4 0.0001
2.9 2.4 0.0001
1.4 2.4 0.0001
are percents unless otherwise stated. The following International Classification of Diseases-9th
ute ischemic heart disease (ICD-9-CM 411), angina (ICD-9-CM 413), atrial fibrillation (ICD-9-CM
D-9-CM 496), cerebrovascular disease (ICD-9-CM 433 to 435), and renal disease (ICD-9-CM 403,
tality
ilure or Mortality
of HF
)
I)
Mortality HR (95% CI)
In Those Who Developed HF
(n  2,316)
In Those Who Did Not Develop HF
(n  771)
.02) 1.07 (1.06–1.08) 1.06 (1.05–1.07)
.13) 1.04 (0.96–1.13) 0.83 (0.72–0.96)
.30) 1.5 (1.37–1.65) 1.17 (0.98–1.40)
.32) 1.24 (1.14–1.35) 1.82 (1.57–2.11)
.54) 1.29 (1.08–1.53) 1.32 (0.91–1.90)
.27) 1.50 (1.30–1.74) 1.66 (1.31–2.11)
.55) 2.21 (1.83–2.67) 2.14 (1.56–2.94)
.75) 1.55 (1.29–1.85) 1.01 (0.65–1.57)
.24) 1.21 (1.09–1.35) 1.00 (0.81–1.24)
.46) 2.63 (2.20–3.15) 1.85 (1.34–2.54)
.16) 0.54 (0.42–0.70) 0.49 (0.29–0.83)
.19) 0.59 (0.47–0.73) 0.75 (0.46–1.24)
.30) 0.45 (0.32–0.62) 0.27 (0.11–0.65)
.34) 0.82 (0.75–0.90) 0.22 (0.16–0.30)
.89) 0.55 (0.50–0.61) 0.14 (0.11–0.18)
.99) 0.58 (0.48–0.72) 0.44 (0.26–0.76)
.18) 1.06 (0.98–1.16) 1.19 (1.03–1.38)al Inf
ex M
r
loped
7 (10.6
22.5
9.3
6.1
3.1
0.9
1.6
3.5
1.7
Values
ther ac
PD) (ICMor
rt Fa
ment
5,871
95% C
.02–1
.02–1
.14–1
.18–1
.20–1
.02–1
.12–1
.30–1
.07–1
.06–1
.91–1
.98–1
.94–1
.19–1
.79–0
.83–0
.06–1viations as in Table 2.
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Post-MI HF December 30, 2008/January 6, 2009:13–20ion in peri-MI mortality, raising the obvious question of
hether improvements in MI care were the major driver of
his phenomenon. The incidence of post-MI HF we report
s substantially higher than previous estimates in the liter-
ture (5–8). Further, we identified that the development of
F, even remotely after a MI, is a sentinel negatively
redictive event (i.e., most of the patients who died were
dmitted for HF in the prior year).
Our data, indicating that concurrent in-hospital HF
onferred a nearly 2-fold increase in mortality risk, supports
revious published reports on the prognostic impact of
I-associated HF. However, we found a much higher rate
f concurrent HF than previously reported. In the WHAS
Worchester Heart Attack Study) trial (1975 to 1995, mean
ge approximately 66 years), there was a decline in the
ncidence of peri-MI in-hospital HF from 38% to 33%. The
n-hospital case fatality rate for WHAS trial patients devel-
ping HF decreased from 33% to 19% over 2 decades, yet
ittle change occurred in the mortality rate in those without
F (7% to 9%) (18). In the NRMI-2 (Second National
egistry of Myocardial Infarction) trial (1994 to 1998, mean
ge approximately 67 years), 19.1% of ST-segment eleva-
ion myocardial infarction (STEMI) patients had HF dur-
ng their index MI hospitalization, and this was associated
ith an OR of 1.68 (95% CI: 1.62 to 1.75) for in-hospital
ortality (19). For patients with STEMI in the GRACE
Global Registry of Acute Coronary Events) study (1999 to
005, mean age approximately 66 years), 19.5% developed
n-hospital pulmonary edema or HF in 1999, but this
roportion had decreased to 11% by 2005 (20). Finally, in a
rior analysis of Albertans of all ages surviving their first
I, we found that 22% developed HF during their index
I hospitalization and 7% developed HF during 32 months
f follow-up; however, the mean age in that study was over
decade younger than in this current study (7). Because
hese studies were composed of relatively younger and select
opulations with prior MI or HF, they are likely less
elevant to the current cohort of elderly patients with their
rst MI. In addition, by excluding prior MI or HF, we
reated an incident cohort to delineate the course of an
therwise relatively healthy but elderly population. This
ohort represents a population of increasing importance that
as been underrepresented in prior studies (21).
Our data are consistent with the decreasing in-hospital
ortality rate for MI over the past decade reported in large
egistries from other locales. For patients of all ages enrolled
n the NRMI-2 trial, the in-hospital mortality rate de-
reased from 10.6% to 9.8% for STEMI patients and from
.9% to 9.1% for other acute coronary syndrome patients
rom 1994 to 1999 (22). Other registry data from a similar
ime period also point to a high in-hospital mortality rate
or STEMI patients (18.7%) and those with a subendocar-
ial MI (13.6%) (23,24). A key novel finding from the
urrent study is our demonstration that the long-term
ortality decrease predominantly related to a decrease inhe index admission mortality rate (5.1% absolute from p994 to 1999), not to a further decline in post-discharge
ortality over the 5 years beyond the hospital stay.
Prior studies of patients surviving an MI reported limited
ata on subsequent, long-term HF incidence and implica-
ions. In a post-hoc analysis of patients enrolled in the
ALIANT (VALsartan In Acute myocardial iNfarcTion)
rial, which enrolled patients in the same time period as our
ohort, 20% of the 775 patients older than 80 years of age
eveloped HF over the next 2 years (25). Importantly, this
ccurred within the context of a randomized controlled trial
mean age 65 years, mean ejection fraction 0.35, one-third
ith a non–Q-wave MI). These patients were not unex-
ectedly on a higher percentage of evidence-based medica-
ions (approximately 35% on a statin and approximately
0% on a beta-blocker) than our patients or those in cohorts
nrolling patients in the same era (26). Further, the shorter
ollow-up precludes definitive long-term conclusions on the
evelopment of HF. In the Framingham study, a modest
ample of patients (n  546, mean age 60 years) with a
-wave MI showed a temporal decline in the mortality rate
ver 40 years, but did not show a long-term decline in the
ncidence of HF post-MI, leading to speculation that
lthough the acute treatment has improved for MI, longi-
udinal outcomes may not have changed (27). In a previous
tudy in Olmsted County, 36% of patients (n  1,537,
ean age 66 years) with an index MI developed HF over
he next 5 years, with a reduction in incident HF from 1979
o 1994 (40% to 33%), the majority of which occurred
ithin the first 2 days, concurrent with an increase with
eperfusion therapy (28). Our study is unique in showing a
emporal increase in the incidence of new-onset HF
ost-MI offsetting the reductions observed in peri-MI
ortality. Further, we have established that the long-term
isk of HF in elderly MI survivors constitutes a much larger
roblem than previously thought, that is, 76% developed
F within 5 years. The reasons for this apparent disconnect
re likely multiple: the increased comorbidity and age of
atients presenting with their first MI, improved (but still
uboptimal) application of revascularization, and improved
hronic oral therapies for cardiovascular disease that delay
ut do not cure the disease.
New-onset HF not only significantly increases the mor-
ality risk among these patients but also augments the
ortality hazard associated with other prognostic factors.
ence, post-MI HF should be viewed as a sentinel event,
kin to those recognized in the palliative care literature for
ther end-stage chronic diseases. Indeed, recent data from
he CHARM (Candesartan in Heart failure: Assessment of
eduction in Mortality and morbidity) study indicates that
he first hospitalization in patients with known HF carries
n adjusted 3-fold risk for death even if not previously
ospitalized for HF, similar to our cohort (29). Even within
he clinical trials of new therapies, the short-term mortality
s low for both STEMI and non-STEMI, and HF is likely
o become an increasingly important component of com-
osite end points. In a recent trial of high-risk STEMI
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December 30, 2008/January 6, 2009:13–20 Post-MI HFatients, the 30-day death rate was 4%; HF incidence as an
nd point was also 4% by 30 days (30). Our long-term
bservations indicate that further evaluation of new thera-
ies may benefit from a long-term assessment beyond the
raditional 90- or 180-day end points.
A unique feature of our analyses was the use of a
ultistate model used to appropriately describe the pathway
hat a patient follows through multiple clinical transitions
nd thereby to model both the competing risks of the
evelopment of HF against death and a survival model for
hose patients who developed HF. In the present analysis,
ompeting risk occurred because the majority of patients
eveloped HF before death, highlighting an underappreci-
ted but clinically significant event. By using the multistate
odel, more of the available information is used, because
nce HF developed, we were able to model the effects of
emographics or comorbidity on subsequent death (16). For
xample, in this cohort, chronic obstructive pulmonary
isease was associated with the development of HF and
ith subsequent mortality if HF developed. However, if HF
id not develop, there was a neutral effect on mortality; the
linical implications of this remain to be determined for
ost-MI patients.
The importance of comorbid cardiovascular and noncar-
iovascular conditions requiring hospitalizations is worthy
f note. For patients who were discharged after their index
I, nearly one-fourth were rehospitalized for MI or other
cute ischemic events within the year. Other vascular disease
lso played an important role; between 1% and 3.5% were
dmitted to the hospital for a stroke or transient ischemic
vent. Clearly, recognition and management of the global
ascular risk of these patients should be at the forefront.
Two therapeutic interventions were associated with a
ower mortality in our cohort: revascularization and medical
herapy. Medication prescription rate at discharge was
onsistent with previous reports from this time period,
ighlighting the similarity between this cohort and other
etailed registries (22). Indeed, the associations we found
or beta-blockers, statins, and ACE inhibitors mirrored the
andomized trial evidence for each agent. Patients who
nderwent revascularization at the index hospitalization did
ot have a reduced incidence of HF; however, if it devel-
ped, they had a lower mortality risk. For example, we
ound statin use was associated with a decreased incidence
f HF and, whether or not it developed, a lower mortality.
n the 4S (Scandinavian Simvastatin Survival Study) trial
esting simvastatin versus placebo, a 30% relative reduction
n mortality and a 21% relative reduction in new-onset HF
as seen in the statin arm (31). However, in the Controlled
osuvastatin Multinational Trial in Heart Failure (median
ge 77 years, ejection fraction 35%), HF patients treated
ith a statin did not have a lower all-cause mortality despite
44% reduction of low-density lipoprotein to 1.96 mmol/l
32). Reconciliation of these disparate results may hinge at
east in part on the difference between preventing HF from
eveloping and treating the HF once it is evident. Mtudy limitations. We used the first MI as the entry point
nto our cohort; however, administrative coding did not
eparate out STEMI from non-STEMI for the time frame
f this study. Given this limitation, it is possible that
nclusion of a lower-risk population of patients with unsta-
le angina will have underestimated the frequency of sub-
equent HF in patients with higher-risk non-STEMI or
TEMI. In the 1993 to 1995 cohort of the Cooperative
ardiovascular Project of Medicare patients using the 410.x
dministrative code for MI, 44% of patients were noted to
ave a subendocardial MI (23). The refinement of biomar-
ers including troponin also took place concurrently with
ur cohort, and although it is unclear what impact this had
n the identification of cases in our cohort, it seems
easonable to hypothesize that this may have led to an
nderestimation of the frequency of HF because outcomes
n higher-risk patients with non-STEMI or STEMI would
e diluted by the lower event rates in lower-risk patients
ith only minor troponin elevations. On the other hand,
hese limitations also mean that it is likely that a population
panning all risk strata was included in our study, thereby
nhancing the applicability of our findings to a general MI
opulation. Similarly, renal failure is an important comor-
idity and is under-represented in our analysis because of
he lack of access to estimated glomerular filtration rate.
ikewise, information on potential eligibility for thrombo-
ytic therapy for patients with STEMI is unavailable in our
atabase because the number of hours from chest pain, or
hether there was an indication or contraindication to
hrombolytics, is not recorded in administrative data.
Left ventricular dysfunction as identified by quantitative
ethods for estimating ejection fraction was not available;
ather, we relied on HF coding from the clinical diagnosis of
F. In the VALIANT trial and other analyses, ejection
raction did not predict future HF hospitalization (25). We
id not include 90 patients (0.8%) with no prior HF
iagnosis but a pulmonary edema ICD-9-CM administra-
ive code on the index MI hospitalization because this code
as not been prospectively validated for subsequent HF
ospitalizations. The 428.x ICD-9-CM administrative
ode has been shown to be accurate for identifying patients
ith symptomatic HF (11). In the TRACE (Trandolapril
ardiac Evaluation) trial, 54% of patients had clinical HF,
f which 76% had left ventricular systolic dysfunction by
maging, leading us to speculate that the true incidence of
eft ventricular systolic dysfunction with or without HF
ymptoms is possibly greater than that reported by us (33).
onclusions
n an elderly cohort of patients with their first MI, the
n-hospital mortality improved over 6 years, but the inci-
ence of in-hospital and subsequent HF increased. Subse-
uent HF is very common after MI in the elderly, particu-
arly in the first year, and confers a substantial risk for death.echanisms to risk stratify and identify elderly patients at
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nd close follow-up constitute a large unmet need.
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